Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CASINO: SGLT2 Inhibitor and Low-Carb Diet in Healthy Volunteers
NCT05662865Phase 1Active, not recruiting
- Sponsor
- AdventHealth Translational Research Institute
- Start
- Mar 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ertugliflozin, sponsored by AdventHealth Translational Research Institute. Primary endpoint: Fasting plasma ketones at 28 days. Started Mar 2023; status: active, not recruiting.
02
Drugs
ertugliflozin
Beyond the preview
Go deeper on NCT05662865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05662865.